Blinklab Limited ( (AU:BB1) ) has shared an announcement.
BlinkLab Limited has announced that North Shore Pediatric Therapy (NSPT), a leader in early autism intervention in Chicago, has joined its US clinical study. NSPT’s participation is expected to enhance the robustness and credibility of the study, which aims to validate BlinkLab’s Dx 1 test as an effective autism screening tool, leveraging NSPT’s expertise in the gold-standard ADOS-2 diagnostic tool and its access to a diverse pool of participants.
More about Blinklab Limited
BlinkLab Limited is an innovative digital healthcare company focused on developing AI-powered smartphone technology aimed at transforming the autism and ADHD diagnostic markets.
YTD Price Performance: 51.79%
Average Trading Volume: 292,196
Technical Sentiment Consensus Rating: Strong Sell
For detailed information about BB1 stock, go to TipRanks’ Stock Analysis page.